Class summary at a glance.

Every drug in the Orexin Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $291.6Mcombined across class
Total Rx claims: 619K172K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Suvorexant

Brand: BELSOMRA · 460K Part D claims (CY24) · 126K beneficiaries · First FDA approval: 2014-08-29

Brand-only (no generics) 156 plans require PA

Low NADAC$15.22

→

Avg plan cost$15.22

Part D spend $222.6M 1× spread, current vs floor

Class share

76%

of class CY24 spend

View profile →

Daridorexant

Brand: QUVIVIQ · 69K Part D claims (CY24) · 21K beneficiaries · First FDA approval: 2022-04-07

Brand-only (no generics) 0 plans require PA

Low NADAC$16.70

→

Avg plan cost$16.71

Part D spend $36.5M 1× spread, current vs floor

Class share

13%

of class CY24 spend

View profile →

Lemborexant

Brand: DAYVIGO · 89K Part D claims (CY24) · 25K beneficiaries · First FDA approval: 2020-04-07

Brand-only (no generics) 38 plans require PA

Low NADAC$11.57

→

Avg plan cost$11.58

Part D spend $32.5M 1× spread, current vs floor

Class share

11%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.